This report provides a comprehensive analysis of the global small nucleic acid therapies market, forecasting steady growth through 2032. It examines key product types, including antisense oligonucleotides, siRNA, and mRNA, alongside diverse applications such as neuromuscular diseases and COVID-19. By evaluating regional dynamics across the Americas, APAC, and Europe, the study highlights emerging opportunities and competitive strategies of major industry players. Furthermore, it explores critical market drivers, technological trends, and the evolving landscape of mergers and acquisitions.

Market Overview

The global Small Nucleic Acid Therapies market is projected to grow from US$ 13090 million in 2025 to US$ 16980 million in 2032, representing an expected compound annual growth rate (CAGR) of 3.9% from 2026 to 2032.

Product Definition

Small Nucleic Acid Therapies are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.

Regional Market Analysis

• United States: The market for Small Nucleic Acid Therapies in the United States is estimated to experience growth from 2025 through 2032.
• China: The market for Small Nucleic Acid Therapies in China is estimated to experience growth from 2025 through 2032.
• Europe: The market for Small Nucleic Acid Therapies in Europe is estimated to experience growth from 2025 through 2032.

Report Scope and Methodology

LPI (LP Information)' newest research report, the “Small Nucleic Acid Therapies Industry Forecast,” reviews total world Small Nucleic Acid Therapies sales in 2025 and looks at past sales. It provides a comprehensive analysis by region and market sector of projected Small Nucleic Acid Therapies sales for 2026 through 2032. With Small Nucleic Acid Therapies sales broken down by region, market sector, and sub-sector, this report provides a detailed analysis in US$ millions of the world Small Nucleic Acid Therapies industry.

This Insight Report provides a comprehensive analysis of the global Small Nucleic Acid Therapies landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Additionally, the report analyses the strategies of leading global companies with a focus on:

• Small Nucleic Acid Therapies portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

This analysis aims to better understand these firms’ unique position in an accelerating global Small Nucleic Acid Therapies market. The report evaluates key market trends, drivers, and affecting factors shaping the global outlook and breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. Using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory in the global Small Nucleic Acid Therapies market. The report presents a comprehensive overview, market shares, and growth opportunities of the Small Nucleic Acid Therapies market by product type, application, key players, and key regions and countries.

Market Segmentation

By Type

• Antisense Oligonucleotides (ASO)
• siRNA
• mRNA

By Application

• Neuromuscular Diseases
• hATTR
• COVID-19
• Other

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Global key Small Nucleic Acid Therapies players include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, and Nippon Shinyaku, among others. In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

The following companies have been profiled based on inputs gathered from primary experts and an analysis of the companies' coverage, product portfolio, and market penetration:

• Sarepta Therapeutics
• Ionis Pharmaceuticals
• Alnylam
• Biogen
• Nippon Shinyaku
• Sobi
• Novartis
• BioNTech
• Pfizer
• Moderna Therapeutics
• Jazz Pharmaceuticals
• CureVac
• Regulus Therapeutics
• ProQR
• Secarna
• MiNA Therapeutics
• Sylentis
• Arrowhead
• Silence Therapeutics
• Dicerna

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Small Nucleic Acid Therapies Market Size (2021-2032)

    • 2.1.2 Small Nucleic Acid Therapies Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Small Nucleic Acid Therapies by Country/Region (2021, 2025 & 2032)

  • 2.2 Small Nucleic Acid Therapies Segment by Type

    • 2.2.1 Antisense Oligonucleotides (ASO)

    • 2.2.2 siRNA

    • 2.2.3 mRNA

    • 2.2.4 Small Nucleic Acid Therapies Market Size by Type

      • 2.2.4.1 Small Nucleic Acid Therapies Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.4.2 Global Small Nucleic Acid Therapies Market Size Market Share by Type (2021-2026)

  • 2.3 Small Nucleic Acid Therapies Segment by Application

    • 2.3.1 Neuromuscular Diseases

    • 2.3.2 hATTR

    • 2.3.3 COVID-19

    • 2.3.4 Other

    • 2.3.5 Small Nucleic Acid Therapies Market Size by Application

      • 2.3.5.1 Small Nucleic Acid Therapies Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.5.2 Global Small Nucleic Acid Therapies Market Size Market Share by Application (2021-2026)

• 3 Small Nucleic Acid Therapies Market Size by Player

  • 3.1 Small Nucleic Acid Therapies Market Size Market Share by Player

    • 3.1.1 Global Small Nucleic Acid Therapies Revenue by Player (2021-2026)

    • 3.1.2 Global Small Nucleic Acid Therapies Revenue Market Share by Player (2021-2026)

  • 3.2 Global Small Nucleic Acid Therapies Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Small Nucleic Acid Therapies by Region

  • 4.1 Small Nucleic Acid Therapies Market Size by Region (2021-2026)

  • 4.2 Global Small Nucleic Acid Therapies Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Small Nucleic Acid Therapies Market Size Growth (2021-2026)

  • 4.4 APAC Small Nucleic Acid Therapies Market Size Growth (2021-2026)

  • 4.5 Europe Small Nucleic Acid Therapies Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Small Nucleic Acid Therapies Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Small Nucleic Acid Therapies Market Size by Country (2021-2026)

  • 5.2 Americas Small Nucleic Acid Therapies Market Size by Type (2021-2026)

  • 5.3 Americas Small Nucleic Acid Therapies Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Small Nucleic Acid Therapies Market Size by Region (2021-2026)

  • 6.2 APAC Small Nucleic Acid Therapies Market Size by Type (2021-2026)

  • 6.3 APAC Small Nucleic Acid Therapies Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Small Nucleic Acid Therapies Market Size by Country (2021-2026)

  • 7.2 Europe Small Nucleic Acid Therapies Market Size by Type (2021-2026)

  • 7.3 Europe Small Nucleic Acid Therapies Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Small Nucleic Acid Therapies by Region (2021-2026)

  • 8.2 Middle East & Africa Small Nucleic Acid Therapies Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Small Nucleic Acid Therapies Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Small Nucleic Acid Therapies Market Forecast

  • 10.1 Global Small Nucleic Acid Therapies Forecast by Region (2027-2032)

    • 10.1.1 Global Small Nucleic Acid Therapies Forecast by Region (2027-2032)

    • 10.1.2 Americas Small Nucleic Acid Therapies Forecast

    • 10.1.3 APAC Small Nucleic Acid Therapies Forecast

    • 10.1.4 Europe Small Nucleic Acid Therapies Forecast

    • 10.1.5 Middle East & Africa Small Nucleic Acid Therapies Forecast

  • 10.2 Americas Small Nucleic Acid Therapies Forecast by Country (2027-2032)

    • 10.2.1 United States Market Small Nucleic Acid Therapies Forecast

    • 10.2.2 Canada Market Small Nucleic Acid Therapies Forecast

    • 10.2.3 Mexico Market Small Nucleic Acid Therapies Forecast

    • 10.2.4 Brazil Market Small Nucleic Acid Therapies Forecast

  • 10.3 APAC Small Nucleic Acid Therapies Forecast by Region (2027-2032)

    • 10.3.1 China Small Nucleic Acid Therapies Market Forecast

    • 10.3.2 Japan Market Small Nucleic Acid Therapies Forecast

    • 10.3.3 Korea Market Small Nucleic Acid Therapies Forecast

    • 10.3.4 Southeast Asia Market Small Nucleic Acid Therapies Forecast

    • 10.3.5 India Market Small Nucleic Acid Therapies Forecast

    • 10.3.6 Australia Market Small Nucleic Acid Therapies Forecast

  • 10.4 Europe Small Nucleic Acid Therapies Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Small Nucleic Acid Therapies Forecast

    • 10.4.2 France Market Small Nucleic Acid Therapies Forecast

    • 10.4.3 UK Market Small Nucleic Acid Therapies Forecast

    • 10.4.4 Italy Market Small Nucleic Acid Therapies Forecast

    • 10.4.5 Russia Market Small Nucleic Acid Therapies Forecast

  • 10.5 Middle East & Africa Small Nucleic Acid Therapies Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Small Nucleic Acid Therapies Forecast

    • 10.5.2 South Africa Market Small Nucleic Acid Therapies Forecast

    • 10.5.3 Israel Market Small Nucleic Acid Therapies Forecast

    • 10.5.4 Turkey Market Small Nucleic Acid Therapies Forecast

  • 10.6 Global Small Nucleic Acid Therapies Forecast by Type (2027-2032)

  • 10.7 Global Small Nucleic Acid Therapies Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Small Nucleic Acid Therapies Forecast

• 11 Key Players Analysis

  • 11.1 Sarepta Therapeutics

    • 11.1.1 Sarepta Therapeutics Company Information

    • 11.1.2 Sarepta Therapeutics Small Nucleic Acid Therapies Product Offered

    • 11.1.3 Sarepta Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Sarepta Therapeutics Main Business Overview

    • 11.1.5 Sarepta Therapeutics Latest Developments

  • 11.2 Ionis Pharmaceuticals

    • 11.2.1 Ionis Pharmaceuticals Company Information

    • 11.2.2 Ionis Pharmaceuticals Small Nucleic Acid Therapies Product Offered

    • 11.2.3 Ionis Pharmaceuticals Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Ionis Pharmaceuticals Main Business Overview

    • 11.2.5 Ionis Pharmaceuticals Latest Developments

  • 11.3 Alnylam

    • 11.3.1 Alnylam Company Information

    • 11.3.2 Alnylam Small Nucleic Acid Therapies Product Offered

    • 11.3.3 Alnylam Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Alnylam Main Business Overview

    • 11.3.5 Alnylam Latest Developments

  • 11.4 Biogen

    • 11.4.1 Biogen Company Information

    • 11.4.2 Biogen Small Nucleic Acid Therapies Product Offered

    • 11.4.3 Biogen Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Biogen Main Business Overview

    • 11.4.5 Biogen Latest Developments

  • 11.5 Nippon Shinyaku

    • 11.5.1 Nippon Shinyaku Company Information

    • 11.5.2 Nippon Shinyaku Small Nucleic Acid Therapies Product Offered

    • 11.5.3 Nippon Shinyaku Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Nippon Shinyaku Main Business Overview

    • 11.5.5 Nippon Shinyaku Latest Developments

  • 11.6 Sobi

    • 11.6.1 Sobi Company Information

    • 11.6.2 Sobi Small Nucleic Acid Therapies Product Offered

    • 11.6.3 Sobi Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Sobi Main Business Overview

    • 11.6.5 Sobi Latest Developments

  • 11.7 Novartis

    • 11.7.1 Novartis Company Information

    • 11.7.2 Novartis Small Nucleic Acid Therapies Product Offered

    • 11.7.3 Novartis Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Novartis Main Business Overview

    • 11.7.5 Novartis Latest Developments

  • 11.8 BioNTech

    • 11.8.1 BioNTech Company Information

    • 11.8.2 BioNTech Small Nucleic Acid Therapies Product Offered

    • 11.8.3 BioNTech Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 BioNTech Main Business Overview

    • 11.8.5 BioNTech Latest Developments

  • 11.9 Pfizer

    • 11.9.1 Pfizer Company Information

    • 11.9.2 Pfizer Small Nucleic Acid Therapies Product Offered

    • 11.9.3 Pfizer Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Pfizer Main Business Overview

    • 11.9.5 Pfizer Latest Developments

  • 11.10 Moderna Therapeutics

    • 11.10.1 Moderna Therapeutics Company Information

    • 11.10.2 Moderna Therapeutics Small Nucleic Acid Therapies Product Offered

    • 11.10.3 Moderna Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Moderna Therapeutics Main Business Overview

    • 11.10.5 Moderna Therapeutics Latest Developments

  • 11.11 Jazz Pharmaceuticals

    • 11.11.1 Jazz Pharmaceuticals Company Information

    • 11.11.2 Jazz Pharmaceuticals Small Nucleic Acid Therapies Product Offered

    • 11.11.3 Jazz Pharmaceuticals Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Jazz Pharmaceuticals Main Business Overview

    • 11.11.5 Jazz Pharmaceuticals Latest Developments

  • 11.12 CureVac

    • 11.12.1 CureVac Company Information

    • 11.12.2 CureVac Small Nucleic Acid Therapies Product Offered

    • 11.12.3 CureVac Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 CureVac Main Business Overview

    • 11.12.5 CureVac Latest Developments

  • 11.13 Regulus Therapeutics

    • 11.13.1 Regulus Therapeutics Company Information

    • 11.13.2 Regulus Therapeutics Small Nucleic Acid Therapies Product Offered

    • 11.13.3 Regulus Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Regulus Therapeutics Main Business Overview

    • 11.13.5 Regulus Therapeutics Latest Developments

  • 11.14 ProQR

    • 11.14.1 ProQR Company Information

    • 11.14.2 ProQR Small Nucleic Acid Therapies Product Offered

    • 11.14.3 ProQR Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 ProQR Main Business Overview

    • 11.14.5 ProQR Latest Developments

  • 11.15 Secarna

    • 11.15.1 Secarna Company Information

    • 11.15.2 Secarna Small Nucleic Acid Therapies Product Offered

    • 11.15.3 Secarna Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 Secarna Main Business Overview

    • 11.15.5 Secarna Latest Developments

  • 11.16 MiNA Therapeutics

    • 11.16.1 MiNA Therapeutics Company Information

    • 11.16.2 MiNA Therapeutics Small Nucleic Acid Therapies Product Offered

    • 11.16.3 MiNA Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 MiNA Therapeutics Main Business Overview

    • 11.16.5 MiNA Therapeutics Latest Developments

  • 11.17 Sylentis

    • 11.17.1 Sylentis Company Information

    • 11.17.2 Sylentis Small Nucleic Acid Therapies Product Offered

    • 11.17.3 Sylentis Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 Sylentis Main Business Overview

    • 11.17.5 Sylentis Latest Developments

  • 11.18 Arrowhead

    • 11.18.1 Arrowhead Company Information

    • 11.18.2 Arrowhead Small Nucleic Acid Therapies Product Offered

    • 11.18.3 Arrowhead Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.18.4 Arrowhead Main Business Overview

    • 11.18.5 Arrowhead Latest Developments

  • 11.19 Silence Therapeutics

    • 11.19.1 Silence Therapeutics Company Information

    • 11.19.2 Silence Therapeutics Small Nucleic Acid Therapies Product Offered

    • 11.19.3 Silence Therapeutics Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.19.4 Silence Therapeutics Main Business Overview

    • 11.19.5 Silence Therapeutics Latest Developments

  • 11.20 Dicerna

    • 11.20.1 Dicerna Company Information

    • 11.20.2 Dicerna Small Nucleic Acid Therapies Product Offered

    • 11.20.3 Dicerna Small Nucleic Acid Therapies Revenue, Gross Margin and Market Share (2021-2026)

    • 11.20.4 Dicerna Main Business Overview

    • 11.20.5 Dicerna Latest Developments

• 12 Research Findings and Conclusion